Hemocompatibility of superhemophobic titania surfaces

Patent metadata

Field	Value
Publication number	US-2018303981-A1
Application number	US-201815954943-A
Country	US
Kind code	A1
Filing date	Apr 17, 2018
Priority date	Apr 20, 2017
Publication date	Oct 25, 2018
Grant date	—

Abstract

In this work, we investigated the blood platelet adhesion and activation of truly superhemophobic surfaces and compared them with that of hemophobic surfaces and hemophilic surfaces. Our analysis indicates that only those superhemophobic surfaces with a robust Cassie-Baxter state display significantly lower platelet adhesion and activation. The understanding gained through this work will lead to the fabrication of improved hemocompatible, superhemophobic medical implants.

First claim

What is claimed is:

1 . A superhemophobic surface comprising:
a fluorinated titania surface having a textured morphology, wherein the fluorinated titania surface is superhemophobic to blood and has a Cassie-Baxter robustness factor (A*) of at least about 5 for blood; wherein the % area of blood platelets (f adh ) that adhere to the fluorinated titania surface having a textured morphology is at least about 10% lower than the f adh of a fluorinated titania surface having a non-textured morphology.

2 . The superhemophobic surface of claim 1 wherein the textured morphology has a feature diameter (2R) of about 1 μm or less than about 1 μm.

3 . The superhemophobic surface of claim 2 wherein the textured morphology has an inter-feature spacing (2D) of about 10 μm or less than about 10 μm.

4 . The superhemophobic surface of claim 1 wherein the textured morphology has a feature diameter (2R) of about 0.05 μm to about 0.5 μm and an inter-feature spacing (2D) of about 0.05 μm to about 5 μm.

5 . The superhemophobic surface of claim 4 wherein the textured morphology is a nanoflower or a nanotube.

6 . The superhemophobic surface of claim 5 wherein the fluorinated titania surface comprises a fluorinated (C 8 -C 18 )alkyl.

7 . The superhemophobic surface of claim 1 wherein A* is about 50 to about 5000.

8 . The superhemophobic surface of claim 7 wherein the surface energy (γ sv ) of the superhemophobic surface is less than about 20 mN m −1 .

9 . The superhemophobic surface of claim 1 wherein the superhemophobic surface is biocompatible.

10 . The superhemophobic surface of claim 9 wherein a blood platelet that adheres to the fluorinated titania surface having a textured morphology does not manifest in platelet aggregation.

11 . The superhemophobic surface of claim 9 wherein a blood platelet that adheres to the fluorinated titania surface having a textured morphology does not manifest in dendritic extensions.

12 . The superhemophobic surface of claim 1 wherein a blood platelet that adheres to the fluorinated titania surface having a textured morphology does not manifest in platelet activation.

13 . The superhemophobic surface of claim 12 wherein the % area of blood platelets (f adh ) that adheres to the fluorinated titania surface having a textured morphology is about 15% to about 95% lower than the f adh of a fluorinated titania surface having a non-textured morphology.

14 . The superhemophobic surface of claim 1 wherein the superhemophobic surface has a contact angle of greater than about 155°.

15 . The superhemophobic surface of claim 14 wherein the superhemophobic surface has a roll off angle of less than about 5°.

16 . A method of fabricating a biocompatible medical device comprising forming the superhemophobic surface of claim 1 on a medical device, wherein a medical device comprising the superhemophobic surface of claim 1 implanted in a subject is biocompatible with the subject and the formation of a blood clot on the medical device comprising the superhemophobic surface is negligible.

17 . A method of fabricating a superhemophobic surface comprising:
a) anodizing a titanium substrate in an electrolyte comprising hydrofluoric acid to form a titania nanotube array; b) annealing the titania nanotube array in a gas comprising oxygen; and c) fluorinating the titania nanotube array to form a superhemophobic surface; wherein the superhemophobic surface has a Cassie-Baxter robustness factor (A*) of at least about 5 for blood.

18 . The method of claim 17 wherein the % area of blood platelets (f adh ) that adheres to the superhemophobic surface is at least about 20% lower than the f adh of a fluorinated non-textured titania surface.

19 . The method of claim 17 wherein a blood platelet that adheres to the superhemophobic surface does not manifest in platelet activation.

20 . The method of claim 17 wherein the formation of a blood clot on the superhemophobic surface is negligible.

Assignees

• Univ Colorado State Res Found

Inventors

• Kota Arun Kumar
• Popat Ketul
• MOVAFAGHI Sanli
• Leszczak Victoria
• Wang Wei

Classifications

• A61L2300/42

  Anti-thrombotic agents, anticoagulants, anti-platelet agents · CPC title

• A61L33/0017 Primary

  using a surface active agent · CPC title

• C01P2004/13

  Nanotubes · CPC title

• A61L2400/12

  Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces · CPC title

• A61L33/04

  Use of organic materials, e.g. acetylsalicylic acid · CPC title